中国银行业规模经济和范围经济的实证研究——基于复合成本函数的分析

本文首次在国内利用复合成本函数估计我国国有商业银行和股份制商业银行1998——2003年的成本函数,并计算出各自的规模经济和范围经济。复合成本函数把投入价格的对数二次项和产出的二次项结合起来,具有优良的实证研究性质。实证研究结果表明:时间对我国银行业的规模经济和范围经济影响不显著;国有商业银行和股份制商业银行都存在着轻微的规模不经济和范围不经济,国有银行略好于股份制银行。我国商业银行的两种产出——存款和贷款不存在成本互补性。     

管理层收购(MBO)与我国国企改革

管理层收购(Management Buy-outs,MBO)广泛流行于欧美国家,为企业提供了一种新的发展模式。近几年来,管理层收购(MBO)在中国也有了较快的发展。本文的宗旨在于对管理层收购自身的优缺点及其在我国的发展现状进行客观评价,进而推动国有企业改革走上健康发展之路。     

基于交易成本的技术标准联盟形成机理研究

技术标准专利化趋势加速了以技术标准联盟设立技术标准的趋势.从交易成本视角看,市场、科层组织和技术标准联盟在技术标准设立过程中都会产生生产成本、机会主义成本、信息成本以及协调成本,相比之下,技术标准联盟在降低交易费用、提高交易质量方面有明显优势,技术标准联盟形成有其合理性.     

Voluntary disclosure and information asymmetry in Denmark

This paper examines if the level of voluntary disclosure affects information asymmetry for industrial companies listed on the Copenhagen Stock Exchange. Economic theory suggests that disclosing more information should lower the information asymmetry component of a firm's cost of capital [Leuz, C., & Verrecchia, R. E. (2000)]. The results indicate that voluntary disclosure is negatively associated with proxies for information asymmetry. The results are robust even after controlling for various firm characteristics introduced in related literature. Despite differences in institutional settings the findings in our paper are similar to the ones based on US data.     

中国国有银行改革的理论与实践问题

当前对国有银行改革的讨论应立足于其初始条件,国有独资银行与商业银行不相容,国有银行具有特殊的职能边界———金融支持国家经济增长;在我国特定的历史阶段,国有银行改革应遵循两种截然相异的路径:完全的股份制或国有独资,而国有控股将导致较高的道德风险;机构利益的独立性并非国有银行的专有问题,通过激励机制设计应该保持国有独资银行的利益从属于中央政府的经济金融政策;国有银行的分支机构和人力资源在不同的改革思路下会具有“历史包袱”和“历史财富”的或然双重性质,关键在于能否从时间序列上观察银行绩效;银行改革成本只能是因支持经济增长和经济体制改革所付出的代价,这一代价的跨期承担优于即期摊销。     

房地产三种评估价格的比较分析

简要的阐述了比准价格、收益价格、积算价格三种房地产评估价格的形成机理及理论依据，并从对一种观点的局限性分析出发，综合运用市场供求理论、均衡理论以及短边原则，对不同市场背景下三种估价方法得出的评估价格进行经济比较分析。     

工程优化设计

加强工程设计方案优化已成为现代工程建设开展的重要工作,是控制工程成本、提高工程造价管理的关键。基于此,论述工程优化设计的影响因素与不足,提出搞好优化设计的几点建议。     

Identifying airline cost economies: An econometric analysis of the factors affecting aircraft operating costs

This paper provides the results of an econometric analysis of the influences of airline characteristics on the average operating costs per aircraft movement. The analysis combines a comprehensive selection of airline-output variables, airline-fleet variables, and airline-market variables. The results confirm the existence of economies of density, economies of load factor, economies of aircraft utilisation and economies of aircraft size. The paper does not provide evidence of economies of scale, economies of stage length or economies of fleet commonality. Furthermore, airlines that additionally operate full freighters, airlines that are members of a worldwide alliance and airlines that operate a multi-hub system face higher average operating costs per aircraft movement. Surprisingly, the regression results demonstrate that airlines that use newer aircraft have higher average operating costs per aircraft movement, suggesting that ownership costs (depreciation and leasing costs) of new aircraft outweigh the increasing maintenance costs of old aircraft. Finally, the results show that airlines that have a dominant position at their hubs or bases have higher operating costs per aircraft movement, implying that the absence of serious competitive pressure enables airlines to charge higher ticket prices and, with that, leads to a limited focus on cost savings.     

Product price and performance level in one market or two separated markets under various cost structures and functions

Market characteristics, including intrinsic demand and customer sensitivity on price and product performance level, are distinct at different markets. Comparisons of various product development strategies in one market or two geographically separated markets are conducted for three classes of products: development intensive products (DIPs) with constant unit cost, marginal cost-intensive products (MIPs) with constant fixed cost, and marginal and development intensive products (MDIPs) with non-constant unit cost and fixed cost. Results show that larger demand size, less customer sensitivity on price and/or more sensitivity on performance level lead to more profit, a higher sale price and a not-lower product performance. The customer reservation or the saturation performance level should be generally adopted though the optimal performance level does exist occasionally. Unit cost and/or fixed cost must increase in performance at an increasing rate for the existence of one optimal performance level. Due to the impact of demand size, one high-end (low-end) MDIP or DIP could be introduced into one low-end (high-end) market at a different price if the demand size is significantly large in the low-end market. For DIPs, offering one niche high-end product is not worse than offering the low-end product into two markets. For MIPs with negligible fixed cost, the product line strategy is not worse than the standard product development strategy. Additionally, the product cost reduction approach adopted in one product line has significant effects on the best product development strategy and sequence.     

Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA

Background and aims: IDegLira, a fixed ratio combination of insulin degludec and glucagon-like peptide-1 receptor agonist liraglutide, utilizes the complementary mechanisms of action of these two agents to improve glycemic control with low risk of hypoglycemia and avoidance of weight gain. The aim of the present analysis was to assess the long-term cost-effectiveness of IDegLira vs liraglutide added to basal insulin, for patients with type 2 diabetes not achieving glycemic control on basal insulin in the US setting.

Methods: Projections of lifetime costs and clinical outcomes were made using the IMS CORE Diabetes Model. Treatment effect data for patients receiving IDegLira and liraglutide added to basal insulin were modeled based on the outcomes of a published indirect comparison, as no head-to-head clinical trial data is currently available. Costs were accounted in 2015?US dollars ($) from a healthcare payer perspective.

Results: IDegLira was associated with small improvements in quality-adjusted life expectancy compared with liraglutide added to basal insulin (8.94 vs 8.91 discounted quality-adjusted life years [QALYs]). The key driver of improved clinical outcomes was the greater reduction in glycated hemoglobin associated with IDegLira. IDegLira was associated with mean costs savings of $17,687 over patient lifetimes vs liraglutide added to basal insulin, resulting from lower treatment costs and cost savings as a result of complications avoided.

Conclusions: The present long-term modeling analysis found that IDegLira was dominant vs liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the US, improving clinical outcomes and reducing direct costs.